- Home
- CEPV vs BWAY Comparison
CEPV vs BWAY Comparison
Compare CEPV & BWAY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CEPV
- BWAY
- Stock Information
- Founded
- CEPV 2021
- BWAY 2003
- Country
- CEPV United States
- BWAY Israel
- Employees
- CEPV N/A
- BWAY N/A
- Industry
- CEPV
- BWAY Medical/Dental Instruments
- Sector
- CEPV
- BWAY Health Care
- Exchange
- CEPV Nasdaq
- BWAY Nasdaq
- Market Cap
- CEPV 326.5M
- BWAY 280.7M
- IPO Year
- CEPV 2025
- BWAY 2019
- Fundamental
- Price
- CEPV $10.30
- BWAY $15.87
- Analyst Decision
- CEPV
- BWAY Strong Buy
- Analyst Count
- CEPV 0
- BWAY 2
- Target Price
- CEPV N/A
- BWAY $20.50
- AVG Volume (30 Days)
- CEPV 1.4M
- BWAY 70.7K
- Earning Date
- CEPV 01-01-0001
- BWAY 11-11-2025
- Dividend Yield
- CEPV N/A
- BWAY N/A
- EPS Growth
- CEPV N/A
- BWAY 189.46
- EPS
- CEPV N/A
- BWAY 0.13
- Revenue
- CEPV N/A
- BWAY $49,094,000.00
- Revenue This Year
- CEPV N/A
- BWAY $335.63
- Revenue Next Year
- CEPV N/A
- BWAY $22.10
- P/E Ratio
- CEPV N/A
- BWAY $49.38
- Revenue Growth
- CEPV N/A
- BWAY 27.08
- 52 Week Low
- CEPV $10.25
- BWAY $7.84
- 52 Week High
- CEPV $10.36
- BWAY $17.92
- Technical
- Relative Strength Index (RSI)
- CEPV N/A
- BWAY 47.36
- Support Level
- CEPV N/A
- BWAY $14.75
- Resistance Level
- CEPV N/A
- BWAY $16.63
- Average True Range (ATR)
- CEPV 0.00
- BWAY 0.72
- MACD
- CEPV 0.00
- BWAY -0.14
- Stochastic Oscillator
- CEPV 0.00
- BWAY 30.91
About CEPV Cantor Equity Partners V Inc. Class A Ordinary Shares
Cantor Equity Partners V Inc is a blank check company.
About BWAY BrainsWay Ltd.
BrainsWay Ltd is engaged in advanced noninvasive neurostimulation treatments for mental health disorders. The company is advancing neuroscience with its proprietary Deep Transcranial Magnetic Stimulation (Deep TMS) platform technology to improve health and transform lives. Current indications include depressive disorder (including reduction of anxiety symptoms, commonly referred to as anxious depression), obsessive-compulsive disorder, and smoking addiction. Additional clinical trials of Deep TMS in various psychiatric, neurological, and addiction disorders are underway. The company derives revenues from the lease and sale of Deep TMS systems.